Moleculin Biotech (MBRX)
(Delayed Data from NSDQ)
$5.02 USD
-0.13 (-2.52%)
Updated May 3, 2024 03:59 PM ET
After-Market: $5.38 +0.36 (7.17%) 7:58 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Brokerage Reports
Moleculin Biotech, Inc. [MBRX]
Reports for Purchase
Showing records 1 - 20 ( 159 total )
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
AACR Poster Strongly Supports Lack Of Annamycin Cardiotox, New CoM Patent
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
4Q23: Solid Annamycin Data, Pivotal Trial Starts In 2024, Funded Into 4Q24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - 36th Annual Roth Conference, Biotechnology Track, March 17-19
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Reports Annamycin Clinical Data as of YE23, Outlines 2024 Milestones
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Investor Event Highlights Reasons for Annamycin Optimism in AML
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Reaching for the Right Tool, Annamycin; Initiate at Buy With a $3.00 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: BERNARDINO V
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Annamycin Continues Delivering Impressive Efficacy in AML at ASH Meeting
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
3Q23: Substantial Progress With Annamycin Trials, Still Funded Into 3Q24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Incrementally More Phase 2 Data Evaluating Annamycin in STS-LM Patients
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Independent Report Shows Lack of Annamycin Cardiotoxicity
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
2Q23: Annamycin Trials Progressing Well, RP2D Determined, Funded Into 3Q24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
1Q23: Annamycin Trials Going Well, Ample 2023 Data Flow, Funded Into 3Q24
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J
Company: Moleculin Biotech, Inc.
Industry: Medical - Biomedical and Genetics
CR in 1st Dose Cohort of Annamycin/Cytarabine in AML, 2nd Cohort Begins
Provider: Roth Capital Partners, Inc.
Analyst: ASCHOFF J